Jiahui International Cancer Center (JICC) says that Satri-cel (CT041, Kaileimei®) has received approval for treatment of a solid tumor. In a June 24, 2026 PR Newswire release from Shanghai, the center describes the approval as a milestone because it is presented as the first CAR-T cell therapy approved for solid tumors. JICC says the approval provides access for patients worldwide, positioning Satri-cel as a new option for people with solid-tumor cancers that meet the therapy’s indicated eligibility under local regulatory requirements. The announcement does not provide clinical details, trial results, or specific cancer types in the excerpt shared, nor does it specify which country’s or regulator’s approval is referenced. The release frames the approval as expanding CAR-T availability beyond blood cancers, but the specific operational steps for patient access are not detailed in the provided text.